Validation of prediction of distant recurrence (DR) by Prosigna (PAM50) in subgroups of a Danish Breast Cancer Cooperative Group (DBCG) cohort of node-positive (N1), hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated 5yr of endocrine therapy (ET).

Abstract

513 Background: N1, HR+ EBC patients are routinely treated with both ET and chemotherapy (CT). Identification of N1 patients with good outcome who may be spared CT remains an elusive goal. In a com...